Mark W Wilson Email & Phone Number

Strategic advice on technology commercialisation and licensing in the life science sector

London, United Kingdom

• From 2008-2017, I creatively developed divestment projects and spin-outs as part of three-person unit, based in GSK’s VC group (SR One) and established a programme developing revenues of millions of dollars plus.
• Initiated and led the divestment of a GSK capsule-based drug delivery technology to Pfizer / Capsugel (developed divestment concept, identified target companies, initiated discussions with CEO and senior management of.
• Licensed a specialised drug development technology (salt and polymorph screening) and divested a 10-person technology team to Catalent (co-led SR One’s first major technology out-licensing project - “Optiform”, for.
• Established a CRO spin-out business from a Polish R&D group (created a 22-person business (PozLab, in Poznan, Poland) within 8 weeks, against a tight deadline; identified opportunity and gained internal support, led.
• Repurposed an abandoned technology as a “personalisable polypill” for personalised medicine / adherence improvement (millions of pounds in funding secured for hypertension studies including work on this approach with.

London, United Kingdom

• From 2008-12, I was seconded on a part-time basis to SR One to create and to execute the spin-out program that is noted above. In addition, I led a major technology strategy initiative and conducted business.
• Pioneered and led personally the key activities to develop an over-arching 15-year technology strategy for formulation and manufacturing for GSK’s Pharmaceuticals division, which gained approval from R&D management.
• Conducted major analyses of technology market potential and prepared business cases for new technologies for R&D board members e.g. combination therapy approaches; personalised-medicine applications
• Led business analysis and influenced senior stakeholders to help to establish the GSK spin-out programme (in SR One) Business Development and Alliance Management (1998-2008):
• Led deal teams on royalty-bearing drug-delivery technology licence transactions, across a range of technologies (patch, inhaled, controlled-release, biological)
• Negotiated and managed over 100 early-stage collaborations; managed alliances up to tens of millions of dollars in total cost, with major clinical programmes; led a strategic review of a major alliance portfolio.

London, United Kingdom

London, United Kingdom

London, United Kingdom

• During 1995-1998 I led international teams to develop new manufacturing processes and conducted manufacturing strategy consultancy
• Led international teams to develop novel drug delivery and manufacturing processes
• Pioneered process modelling approaches in GSK
• Negotiated to halt construction of a dangerous multi-million-dollar high-active production facility, leading to new corporate-wide systems
• Led capital investment analysis for central strategy groups on multi-million dollar programmes

Worthing, United Kingdom

Worthing, United Kingdom

• During 1993-95 I worked on improvements to processes for the large-scale extraction of fermented pharmaceutical products, and undertook a year-long secondment to an operating plant, with responsibility for managing.
• Initiated and managed activities to provide the first fully-validated plant in the SmithKline Beecham factory network
• Led FDA pre-approval inspection activities for a manufacturing plant, managing all engineering activities

Master Of Business Administration (Mba) - Executive Mba Global

Activities and Societies: Accomplished an elective "double concentration" in finance and strategy in this prestigious two-school programme

Doctor Of Philosophy (Phd), Chemical Engineering

Activities and Societies: Thesis topic - "Biosorption for the Treatment of Industrial Wastewaters" • Created and led new group of 8.

Master Of Engineering (Meng), Chemical Engineering

Activities and Societies: • Awarded a special prize for the final year design project, scoring the highest mark in the year cohort